John R. Pollard, M.D.

Director, ChristianaCare Epilepsy Center ChristianaCare

  • Wilmington DE

Dr. Pollard is an expert in treatment of drug resistant epilepsy in adults.

Contact

ChristianaCare

View more experts managed by ChristianaCare

Biography

John R. Pollard is a neurologist who specializes in epilepsy, which affects 2.3 million adults and nearly 500,000 children in the United States.

Areas of Expertise

Epilepsy Clinical Trials
Drug Resistant Epilepsy
Epilepsy Biomarkers

Education

Hospital of the University of Pennsylvania

Residency

Neurology

University of Pennsylvania School of Medicine

MD

Multimedia

Media Appearances

His seizure sparked terrifying fall that uncovered long-sought answer

The Washington Post  print

2022-10-15

“I remember him saying, ‘I can’t believe this happened in front of my family,’ ” recalled his longtime neurologist John R. Pollard, formerly associate director of the epilepsy center at the University of Pennsylvania. Pollard had warned Caldwell that his intractable seizures, which had proved resistant to numerous medications, placed him at risk for sudden death or serious injury.

View More

Evogen's Cognizance Biomarkers Presents Data Showing Its Proteomic Biomarkers Have the Potential to Monitor Seizure Burden to Aid in Epilepsy Patient Management

BioSpace  

2019-05-28

John Pollard, MD, who is an inventor of the Cognizance Biomarkers technology, a practicing neurologist, Director of the Christiana Care Epilepsy Center and Adjunct Associate Professor of Neurology at the University of Pennsylvania's Perelman School of Medicine, commented, "Epilepsy diagnosis can be difficult and slow, with misdiagnosis and suboptimal treatment too often taking years to correct. We undertook development of a proteomic-based blood test to provide an accurate, objective and rapid alternative. Cognizance's first product, the EvoScoreDXTM test, has demonstrated the potential to identify epileptic seizures with excellent sensitivity and specificity. This approach has now been expanded to allow for the accurate monitoring of therapy-associated improvements in the frequency of seizures, which should make it easier to optimize treatment over the lifecycle of the condition."

View More

First in-Patient Adult Epilepsy Monitoring Unit Opens in Delaware

Newswise  

2018-06-20

“We want to help patients who believe they have been over-diagnosed or under-diagnosed so they can see improvement in their lives,” said Neurologist John R. Pollard, M.D., medical director of the new EMU.

View More

Selected Papers and Publications

Association of Epileptic and Nonepileptic Seizures and Changes in Circulating Plasma Proteins Linked to Neuroinflammation

Neurology

2021-01-25

To develop a diagnostic test that stratifies epileptic seizures (ES) from psychogenic nonepileptic seizures (PNES) by developing a multimodal algorithm that integrates plasma concentrations of selected immune response-associated proteins and patient clinical risk factors for seizure.

View more

Trends in oral anticoagulant co-prescription with antiepileptic drugs among adults with epilepsy, 2010-2018

Epilepsy Behavior

2020-11-24

Treatment considerations for epilepsy patients requiring anticoagulation are changing, and actual prescribing practices have not been characterized.

View more

The Impact of COVID-19 on Epilepsy Care: A Survey of the American Epilepsy Society Membership

Epilepsy Currents

2020-09-17

The COVID-19 pandemic has impacted the delivery of care to people with epilepsy (PWE) in multiple ways including limitations on in-person contact and restrictions on neurophysiological procedures.

View more

Show All +

External Service & Affiliations

  • American Board of Psychiatry and Neurology
  • American Board of Clinical Neurophysiology

Patents

Biomarkers and methods for detection of seizures and epilepsy

WO2017120166A1

2017-07-13

Epileptic seizures are difficult to diagnose and are often difficult to distinguish from several conditions with similar presentations, and therefore, diagnosis of seizures is often a long, expensive, and unreliable process.

View more